A study to determine the effect of sampling time on serum periostin levels in adult participants with and without asthma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12614000072617

Acronym

PER06

Enrollment

Registered

2014-01-21

Start date

2014-07-22

Completion date

2014-09-15

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Levels of POSTN (a protein-coding gene, also known as osteoblast specific factor) gene expression and periostin have been measured in a number of tissues and disease states, including asthma. As yet an incomplete picture is currently available on the role and effects of periostin level in the blood, however it has shown promise as a biomarker for asthma severity and a marker of inflammation levels, being easy to measure through a simple blood test. This study of the sample time variation of periostin in patients with stable asthma compared with patients without asthma would provide further information on the production of periostin and whether sampling time affects the level of periostin measured in the blood, and if there is a difference between the general population and asthmatics in this regard. This study is part of a programme of research being undertaken by the Medical Research Institute of New Zealand, aimed at furthering knowledge of periostin, in order to discover its clinical usefulness.

Interventions

Serum Periostin level. Serum Periostin levels will be measured 6 times at a single visit, results will be obtained via a specific periostin laboratory assay. Baseline measurement will take place between 7-9am and 5 further measurements will be taken at 2 hourly intervals, on the day of the clinic visit

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

Aged between 18 to 75 years Able to provide written informed consent Doctor diagnosis of asthma and on stable dose of Inhaled Corticosteroids (ICS) and/or Long Acting Beta Agonist (LABA) for past 3 months, OR no doctor diagnosis of asthma and no wheeze for past 12 months.

Exclusion criteria

Documented lung condition other than Asthma (prior diagnosis or discovered as part of screening assessments) Known pregnancy Significant co morbidities (determined at investigator discretion) Hospital admission within last 3 months Surgery within last 3 months, determined at investigator discretion (this includes all major surgery requiring general anaesthetic, dental extractions and root canal procedures. This does not include minor procedures, including but not limited to mole or wart removal, dental fillings etc). Bone fracture within the last 3 months Oral or Systemic Corticosteroids within the last 3 months Any other safety concern at the investigator’s discretion

Outcome results